Please login to the form below

Not currently logged in
Email:
Password:

axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer

VEGF-targeting Inlyta (axitinib).

Latest news

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics